Population Pharmacokinetic Estimates Suggest Elevated Clearance and Distribution Volume of Desethylamodiaquine in Pediatric Patients with Sickle Cell Disease Treated with Artesunate-Amodiaquine

George O. Adjei, MD, PhD1,*, Seth K. Amponsah, PhD2, Bamenla Q. Goka, MB. ChB, MRCP, FWACP3, Christabel Enweronu-Laryea, MBBS, MSc, FRCPCH3, Lorna Renner, MB. ChB, MPH, FRCPCH, FGCP3, Abdul Malik Sulley, MSc1, Michael Alifrangis, MSc, PhD4, Jorgen A.L. Kurtzhals, MD, PhD4

1 Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana
2 Department of Pharmacology and Toxicology, School of Pharmacy, College of Health Sciences, University of Ghana, Accra, Ghana
3 Department of Child Health, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana
4 Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology University of Copenhagen and Department of Clinical Microbiology and Department of Infectious Diseases, Copenhagen University Hospital (Righishospitalet), Copenhagen, Denmark

ARTICLE INFO

Article history:
Received 22 October 2018
Revised 5 January 2019
Accepted 8 January 2019

Key words:
Clearance
Desethylamodiaquine
Sickle cell disease

ABSTRACT

Background: There is limited information on the safety or efficacy of currently recommended antimalarial drugs in patients with sickle cell disease (SCD), a population predisposed to worse outcomes if affected by acute malaria. Artesunate-amodiaquine (ASAQ) is the first-line treatment for uncomplicated malaria (UM) in many malaria-endemic countries and is also used for treatment of UM in SCD patients. There is, however, no information to date, on the pharmacokinetics (PK) of amodiaquine or artemesunate or the metabolites of these drugs in SCD patients.

Objectives: This study sought to determine the PK of desethylamodiaquine (DEAQ), the main active metabolite of amodiaquine, among paediatric SCD patients with UM treated with artemesunate-amodiaquine (ASAQ).

Methods: Plasma concentration-time data (median DEAQ levels) of SCD children (n = 16) was initially compared with those of concurrently recruited non-SCD paediatric patients with acute UM (n = 13). A population PK modelling approach was then used to analyze plasma DEAQ concentrations obtained between 64 and 169 hours after oral administration of ASAQ in paediatric SCD patients with acute UM (n = 16). To improve PK modeling, DEAQ concentration-time data (n = 21) from SCD was merged with DEAQ concentration-time data (n = 169) of a historical paediatric population treated with ASAQ (n = 103) from the same study setting.

Results: The median DEAQ concentrations on days 3 and 7 were comparatively lower in the SCD patients compared to the non-SCD patients. A two-compartment model best described the plasma DEAQ concentration-time data of the merged data (current SCD data and historical data). The estimated population clearance of DEAQ was higher in the SCD patients (67 L/h, 21% relative standard error (RSE) compared with the non-SCD population (15.5 L/h, 32% RSE). The central volume of distribution was larger in the SCD patients compared with the non-SCD patients (4400 L. 43% RSE vs. 368 L, 34% RSE).

Conclusions: The data shows a tendency towards lower DEAQ concentration in SCD patients and the exploratory population PK estimates suggest altered DEAQ disposition in SCD patients with acute UM. These findings, which if confirmed, may reflect pathophysiological changes associated with SCD on DEAQ dispo-

* Address correspondence to: George O. Adjei, MD, PhD, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana.

E-mail address: gadjei@ug.edu.gh (G.O. Adjei).

https://doi.org/10.1016/j.curtheres.2019.01.005
0011-393X/© 2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
sition, have implications for therapeutic response to amodiaquine in SCD patients. The limited number of recruited SCD patients and sparse sampling approach however, limits extrapolation of the data, and calls for further studies in a larger population.

© 2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Sickle cell disease (SCD) is a common autosomal recessive genetic disorder caused by a single nucleotide substitution (T->A) in the sixth codon of the β-globin gene. The single point mutation resulting in a Glu to Val substitution promotes polymerization and precipitation of haemoglobin S (HbS) during deoxygenation or dehydration, resulting in sickling of red blood cells. The associated pathophysiological changes result in vaso-occlusive crises and other clinical manifestations of SCD, and ultimately, organ damage. The highest frequencies of homozygous SCD are found in sub-Saharan Africa, and although a linkage exists between the presence of sickle haemoglobin (HbS) and protection from malaria in the heterozygous state, malaria is a frequent cause of hospitalization and poor outcome among children with homozygous SCD in endemic areas; and malaria is associated with a higher mortality in hospitalized SCD patients. These imply the need to ensure efficacious antimalarial therapy in SCD patients who develop acute malaria but information on the efficacy or safety of recommended antimalarial drugs in SCD patients is limited or non-existent.

Amodiaquine (AQ) is currently used in combination with artesunate (AS) as first-line treatment for uncomplicated falciparum malaria (UM) in many countries. AQ is a 4-aminoquinoline metabolized by hepatic cytochrome P450 2C8 (CYP2C8) to desethylamodiaquine (DEAQ) its active metabolite, which is subsequently eliminated via extra-hepatic biotransformation by CYP1A1 and CYP1B1. DEAQ is primarily responsible for the pharmacological activity of AQ (parent drug), due to its long elimination half-life.

The pharmacokinetics (PK) of AQ when used in combination with artesunate (AS), has been described in healthy volunteers, and children, and adults, with UM. Estimates of DEAQ clearance have been reported to range between 6–17 L/h and distribution volume between 350–500 L in non-SCD children. There is the possibility that the disposition of AQ could be altered in patients with SCD given anticipated pathophysiological changes in SCD patients. It is known that both white blood cells and platelets accumulate large amounts of chloroquine, therefore, excessive thrombocytosis or leukocytosis, both of which are features of SCD, could alter the distribution of this 4-aminoquinoline in blood. Indeed, plasma concentrations of chloroquine and desethylchloroquine, its major metabolite have been shown to differ between SCD and non-SCD erythrocytes in vivo and in vitro. There are no reports on the PK of AQ or DEAQ in SCD patients. In this study, the PK of DEAQ in paediatric SCD patients with acute UM who participated in a clinical trial and received treatment with ASAQ is described.

Methods

Study site

The study was a sub-component of a clinical trial (ISRCTN6891086) that was conducted to evaluate the efficacy and safety of ASAQ and artemether-lumefantrine (AR-L) among SCD and non-SCD children with acute UM. The study was conducted at the Outpatients Department (OPD) and Paediatric Sickle Cell Clinic of the Department of Child Health, Korle Bu Teaching Hospital, Accra, Ghana, between January 2010 and December 2011. The full details of the clinical trial have been previously reported. Briefly, children of known SCD status registered at the Paediatric Sickle Cell Clinic who presented to the Paediatric Emergency Department or the Paediatric Sickle Cell Clinic with an acute febrile illness confirmed parasitologically to be UM were recruited, if they fulfilled study criteria and if written informed consent was obtained from an accompanying parent or guardian. Recruited children were treated with ASAQ or AR-L and followed up on days 1, 2, 3, 7, 14, 28, 35, and 42, according to a pre-defined schedule. Ethical approval was obtained from the Ethical and Protocol Review Committee, University of Ghana Medical School. Inclusion criteria for the study were, child of confirmed SCD status aged six months to 12 years with an acute febrile illness (history of fever within the previous 72 hours, or an axillary temperature ≥37.5°C at presentation; Plasmodium falciparum infection of parasite density <200,000/μL; and, willingness of the accompanying parent/guardian to comply with the study procedures and follow-up schedule). Exclusion criteria were, symptoms or signs of severe malaria; known intolerance or allergy to study medications; and, reported treatment with any of the study drugs one-month preceding enrolment.

Drug dosing

ASAQ (Coarsucam; Sanofi Aventis, France; 25/50/100 mg arte-AB and 67.5/135/270 mg amodiaquine) single daily dose, was administered for three days according to body weight: ≥4.5 - <9 kg (25 mg/67.7 mg), one tablet/dose; ≥9 - <18 kg (50 mg/135 mg), one tablet/dose; ≥18 - <36 kg (100 mg/270 mg), one tablet/dose; ≥36 kg (100 mg/270 mg) two tablets/dose.

Blood sampling

A venous blood sample (2–5 ml) was collected into heparinized polypropylene tubes before treatment and on days 3 or 7 in children who were haemodynamically stable and/or in whom a blood sample was required for laboratory analysis for clinical management. The heparinized blood was immediately centrifuged, and plasma was transferred into polypropylene tubes and stored at −20°C until analysis. The exact time of drug administration was recorded for each participant on days 0, 1, and 2, and the exact time of blood sampling was recorded on days 3 or 7.

High Performance Liquid Chromatographic (HPLC)

The concentrations of DEAQ were measured in plasma by means of a reverse-phase HPLC method. Heparinized plasma samples (100 μl) were pipetted into 10 ml glass tubes and 90 μl milli-Q water, 200 μl sodium carbonate buffer (0.2 M, pH 9.5) and 2000 μl tert-butylmethyl ether were added. After reciprocal shaking for 20 min. and centrifugation (3000 rpm., 10 min.) the organic phase was transferred to new tubes and extracted for 20 min. with 120 μl of phosphate buffer (0.1 M, pH 4). After separation, the organic phase was discarded, and the aqueous phase was transferred into polypropylene HPLC vials. Aliquots of 90 μl were injected into
the chromatograph. The HPLC system consisted of an 1100 Quato-
metric pump with 1100 Degasser and an 1100 Autosampler (Agilent
Technologies (Palo Alto, CA, USA) with a Zorbax SB-CN column,
5μm (4.6 × 250 mm) (Agilent), protected by a LiChrosart® 4-4
LiChrospher® 100 RP-18 (5 μm) guard column (Merck, Darmstadt,
Germany). The mobile phase was acetonitrile-phosphate buffer
(0.1 M, pH 2.3)-sodium perchlorate (1 M) (14:85:1) operating at
a flow rate of 1.2 ml/min. The wavelength was set at 237 nm
(1100 Diode array detector, Agilent Technologies). The within-day,
intra-assay variation was determined by replicate analysis of samples
spiked with different concentrations. The between-day, inter-assay variation was performed by two determinations at
each concentration on different days. Five calibrators were run in
duplicate each day of analysis. Accuracy was determined by repli-
cate analysis of spiked plasma samples. The recovery in plasma
at three different concentrations were determined by comparing
peak areas obtained after extraction of spiked human plasma with
those of directly injected standards dissolved in the mobile phase.
The limit of quantitation (100 μl) was 10 ng/ml, and coefficient of
variation (CV) was <10%.

PK model building

The total AQ dose, number of administered (AQ) doses, sampling and dosing times, plasma DEAQ concentrations, and
demographic information was available. The sampling time was
calculated relative to the time of first drug administration, and
drug concentrations below LOQ (3 time points) were excluded.

A nonlinear mixed-effects modeling approach was applied to estimate the PK parameters of DEAQ, using NONMEM
(Version 7.3, ICON Development Solutions, Ireland), with Pirana®
software (Version 2.8.2, Pirana Software and Consulting BV) and the First Order Conditional Estimation with Interaction
(FOCEI) algorithm for the model building. Graphical analysis of model out-
puts and covariate analysis were explored, using R Software® (Ver-
sion 3.0.2), and R Package Xpose® (Uppsala University, Sweden).

Due to a high eta-shrinkage and poor goodness of fit plots (due
to the sparse data and limited sample size) from the 16 sickle
cell disease (SCD) children (21 concentration-time points), and 13
non-sickle cell patients (14 concentrations-time points), the data
from the SCD patients was merged with a previous dataset that
described the PK of DEAQ in 103 non-SCD children (169 mea-
surable DEAQ concentration-time points) with UM in the same
study setting.13 giving a total of 190 concentration time points.
Of these 103 children, 15 (median age = 5.3 years; median body
weight = 18 kg) received AQ only, whilst 88 (median age = 6.0
years; median body weight = 18 kg) received A5 plus AQ. After
merging the data, SCD was included in the model as categorical
covariate.

For the structural PK model, one- and two-compartmental
models with first order absorption were fitted to the plasma DEAQ
concentration-time data. The two-compartment model appeared
to describe data better, based on the objective function. Due to
the lack of data on the absorptive phase of AQ disposition, the
absorption rate constant (Kα) and lag time (Tlag) were fixed at
0.867 h⁻¹ and 0.84 h, respectively, as described previously.13
Furthermore, the fixed Ka was viewed as a hybrid parameter that
includes the Ka of AQ, the volume of distribution (V₅) of AQ, and
the formation clearance (Cl/F) of DEAQ, as described previously.13
Therefore, the two-compartment model was parameterized as clearance
(Cl/F), central volume of distribution (V2/F), intercompartment-
tal clearance (Q/F), and peripheral volume of distribution (V3/F).
Between patient variability (BPV) was modeled exponentially
assuming a log normal distribution. BPV was estimated assuming
parameters had a mean of zero, and a variance of omega squared
(ω²). Additive, proportional and combined error models were
tested in the model building process, and residual error was as-
sumed to have a mean of zero and variance of sigma squared (σ²).
The effect of age, body weight and sex were explored as covariates
on the PK parameters. These covariates were retained in the model
if they improved fit (backward elimination and forward inclusion).
Allometric scaling of all distribution parameters were done as re-
ported by Holford.22 Models were compared by the likelihood ratio
test, represented in NONMEM as a difference in objective function
value (ΔOFV) of 3.84, and corresponding to a level of significance
of <0.05, and by using a decrease in the variance of random
effects, eta-shrinkage and goodness of fit plots [observed (DV) vs.
individual-predicted (IPRED) and population predicted (PRED), as
well as conditional weighted residuals (CWRES) vs. PRED].

The model that best described the data was evaluated by means
of visual predictive check (VPC).

Statistical analysis

Entire pharmacokinetic modeling process (software used, de-
scription of structural and statistical models, model compar-
ison and evaluation) have been described earlier. Continuous
variables were summarized as medians with accompanying ranges,
and group medians compared with Wilcoxon signed-rank test.
A p value <0.05 was considered statistically significant.

Results

Characteristics of patients and plasma DEAQ concentrations on days 3 and 7

All recruited participants demonstrated an adequate clinical and
parasitological response. The median age of the SCD patients
was higher, and admission parasitaemia was lower, compared to the
non-SCD group. There was a total of 35 measurable plasma DEAQ
concentrations above LOQ from 16 SCD (n = 21), and 13 non-SCD
(n = 14) patients obtained between 64.3 and 169.2 hours. There
were comparatively lower (though statistically non-significant)
DEAQ concentrations amongst the SCD children compared to the
non-SCD children on Days 3 (p = 0.27) and 7 (p = 0.12). The
baseline demographic characteristics and median DEAQ concentra-
tions of SCD and non-SCD children on day 3 (SCD, n = 10: non-SCD,
n = 8) and day 7 (SCD, n = 11: non-SCD, n = 6) is shown (Table 1).

Population PK modelling of DEAQ plasma concentrations of merged data [SCD (n = 16) and non-SCD (n = 103) children]

The DEAQ plasma concentration from the merged data of
SCD children (21 concentration-time points) and non-SCD (169

Table 1
Baseline demographic characteristics and plasma levels of desethylamodiaquine (DEAQ) on days 3 and 7 after administration of first amodiaquine dose among recruited children with sickle cell disease (SCD) and without SCD.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SCD (n = 16)</th>
<th>No SCD (n = 13)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>9 (1.9–13.8)</td>
<td>6 (2–11)</td>
<td>0.15</td>
</tr>
<tr>
<td>Male sex</td>
<td>6 (37.5)</td>
<td>7 (53.8)</td>
<td></td>
</tr>
<tr>
<td>median (range)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parasite density (μL)</td>
<td>652 (48–63,360)</td>
<td>24240 (160–148,160)</td>
<td>0.001</td>
</tr>
<tr>
<td>Haemoglobin (g/dL)</td>
<td>6.3 (3.6–12.8)</td>
<td>10 (5.8–12.2)</td>
<td>0.004</td>
</tr>
<tr>
<td>White blood cells (10^3/L)</td>
<td>12.8 (6–73.4)</td>
<td>9.3 (6.1–19.3)</td>
<td>0.14</td>
</tr>
<tr>
<td>Platelet count (10^9/L)</td>
<td>201 (67–813)</td>
<td>152 (41–283)</td>
<td>0.03</td>
</tr>
<tr>
<td>Day 3 DEAQ (ng/mL)</td>
<td>72.0 (20–169.3)</td>
<td>117.6 (36–317)</td>
<td>0.27</td>
</tr>
<tr>
<td>Day 7 DEAQ (ng/mL)</td>
<td>19.0 (14–70)</td>
<td>32.2 (14–51.5)</td>
<td>0.12</td>
</tr>
</tbody>
</table>
concentration-time points) showed that a two-compartment best described the base model. The PK parameter versus covariate plot of the merged data showed that body weight would explain some of the variability in DEAQ clearance, as shown in Figure 1. Parametrization of the two-compartment model and application of allometric scaling yielded a much better fit, and diagnostic plots of the best model that described data are shown (Figures 2A and B). This model had a variance in BPV of 32.6% on CL (25% shrinkage) and 49.6% on $V_z$ (67% shrinkage). A set of simulated datasets generated, using the best model was compared to real observations, i.e., VPC, which showed that the sparse (plasma DEAQ) observations limited the creation of an appropriately robust model for the current dataset. The VPC of the historical dataset (Figure 3A), and the DEAQ data of the children with SCD (Figure 3B), are shown.

The parameter covariate plots of CL and central volume of distribution ($V_z$) of DEAQ among non-SCD and SCD children of the merged dataset, with inclusion of SCD as a categorical covariate in the model, are shown (Figures 4A and B), respectively. The population clearance and volume of distribution of DEAQ in SCD and non-SCD children is summarized in Table 2. Population CL was found to be approximately 5-fold greater in the SCD children compared to the non-SCD children. The population $V_z$ of DEAQ for the children with SCD children was more than 10-fold that of the non-SCD children.

**Discussion**

In this study, we used a population PK modelling approach to estimate selected primary PK parameters of DEAQ in a limited sample of SCD children versus non-SCD children treated with ASAQ for acute uncomplicated *falciparum* malaria. We are not aware of any previous report on the PK of antimalarial drugs in SCD patients with acute malaria. The data is consistent with previous studies that have showed wide inter-individual variation in DEAQ concentrations. The relatively low day 3 and day 7 plasma DEAQ concentrations in the SCD patients are comparable to similarly low plasma DEAQ concentrations demonstrated in HIV-infected children treated with ASAQ, but almost two-fold lower on average, than plasma DEAQ concentrations of non-SCD children.

The low day 3 DEAQ concentrations in the SCD patients could be due to excessive thrombosis and leukocytosis in SCD patients, and to associated pathophysiological changes in SCD including hyposthenuria and hyperfiltration, which could be acting in concert with increased hepatic and renal blood flow from increased cardiac output or chronic haemolytic anaemia, to accelerate solute (drug) clearance. Impaired hepatic and renal blood flow has been linked to elevated morphine clearance in SCD patients, and to impaired lidocaine metabolism. The large differences in clearance and volume of distribution is also consistent with the results of several studies that have shown differences in PK parameters between SCD and non-SCD populations for various drugs: the clearance of ciprofloxacin is reported to be 89% higher in SCD patients compared to non-SCD patients; cefotaxime clearance has been shown to be higher in SCD patients, and higher still in SCD patients with acute chest syndrome; and morphine clearance is reported to be 3–10 fold higher in SCD patients compared to published estimates in the non-SCD population. The chronic inflammation in SCD may also induce drug metabolism, as demonstrated for codeine in SCD patients. It is also plausible that other commonly occurring changes in SCD patients including malnutrition and hypoalbuminaemia, increases the unbound drug concentration and thus, alter the kinetics of drug disposition. However, due to the physicochemical characteristics of amodiaquine, the overall pharmacodynamic effect(s) of these PK parameter changes in SCD patients, on the therapeutic effect of amodiaquine, given the interplay of multiple factors, is difficult to anticipate.

The limitation of the study is the limited sample and sparse dataset and resulting high shrinkage on the PK parameter estimates. These places limitations on the robustness of the model and on interpretation or extrapolation of the findings. These limitations notwithstanding, we consider the data and findings to be potentially important because there is lack of data on the pharmacokinetics of amodiaquine, a widely used antimalarial drug, in SCD and non-SCD patients. Given the higher malaria-associated mortality in SCD, difficulty in recruiting sufficient number of parasitologically-

![Figure 1. Clearance derived from the base model of merged data versus body weight. Red line shows line of best fit (or line of correlation)](image-url)
confirmed malaria patients among SCD patients, the difficulties of taking multiple blood samples from such a chronic haemolytic anaemia prone paediatric SCD patients and the ethical implications of multiple blood sampling in such a vulnerable population, the findings from this limited dataset, obtained during routine clinical procedures, provides important preliminary information in a population in which such information is lacking and in which such a dataset is difficult to obtain.

In summary, we have employed a population modelling approach (merging sparse SCD data with historical data) to estimate primary PK parameters of DEAQ in paediatric SCD patients, a population in which such data is lacking. The findings suggest altered DEAQ disposition in SCD patients which calls for further studies and raise questions on potential therapeutic effects of these changes on amodiaquine use in SCD patients.
Figure 3. A: Visual Predictive Check (VPC) of DEAQ observations (ng/ml) versus time (h) of non-SCD (n = 103). B: Visual Predictive Check (VPC) of DEAQ observations (ng/ml) versus time (h) of SCD (n = 16). Blue half circles are individual observations, solid and dotted red lines – observation percentile intervals (upper 5%, lower 5% and a median), the blue and orange areas are 95% confidence intervals around each of the prediction percentile intervals obtained by simulation.

Figure 4. A: Population Clearance (L/h) of DEAQ derived from the most appropriate model after merged data among SCD and non-SCD children. B: Population V2 (L) of DEAQ derived from the most appropriate model after merged data among SCD and non-SCD children. SCD: Sickle cell disease children. Non-SCD: Non-sickle cell disease children

Acknowledgements

We thank Kim Kristensen for advice on the population pharmacokinetic analysis.

Conflicts of Interest

None to declare. The study was funded by grants from the Consultative Forum for Development Research (FFU-DANIDA), Danish Ministry of Foreign Affairs (DFC project no. 09-080RH).

References

6. Ambre JP, Fatunde JO, Sodeinde OO. Associated morbidities in children with sickle-
le-cell anaemia presenting with severe anaemia in a malaria area. Trop Doct.

7. Makani J, Komba AN, Cox SE, Oruo J, Mwamtemi K, Kitundu J, Magesa P, Rweta-
ula S, Meda E, Mgaya J, Pallangyo K, Okiro E, Muturi D, Newton CR, Fegan G,
Marsh K, Williams TN. Malaria in patients with sickle cell anemia: burden, risk
factors, and outcome at the outpatient clinic and during hospitalization. Blood.

Scott JA, Marsh K, Williams TN. High mortality from Plasmodium falciparum

9. Li QX, Bjorkman A, Andersson TB, Riddister M, Masimirembwa CM. Amodi-
IQUE clearance and its metabolism to N-desethylamiodquine is mediated by
CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J

10. Churchill FC, Parthen LC, Campbell CC, Schwartz IK, Nguyen-Dinh P, Dickin-
son CM. Amodiaquine as a produg: importance of metabolite(s) in the anti-

and tolerability of artesunate and amodiaquine alone and in combination in

12. Navaratnam V, Ramanathan S, Wahab MS, Siew Hua G, Mansor SM, Kiechel JR,
Vaillant M, Taylor WR, Olliaro P. Tolerability and pharmacokinetics of non-fixed
and fixed combinations of artesunate and amodiaquine in Malaysian healthy

13. Adjei GO, Kristenzen K, Goka BQ, Horgeb LC, Alifrangis M, Rodrigues OP,
Kurtzhals JA. Effect of concomitant artesunate administration and cytochrome
P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian
2008;52(12):4400–4406.

Simpson JA, Morgan CC, White NJ, Kiechel JR. Population pharmacokinet-
ics of artesunate and amodiaquine in African children. Malar J. 2009;8:
269.

15. Mweigiwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, Clark TD,
Dorsey G, Lindegard N, Annberg A, Rosenthal PJ, Kamya MR, Aweke F, Phar-
macokinetics of artesunate-lumefantrine and artesunate-amodiaquine in chil-

16. Jullien V, Ogutu B, Juma E, Cari N, Obyonyo C, Kiechel JR. Population pharma-
cokinetics and pharmacodynamic considerations of amodiaquine and des-
etyhydroamodiaquine in Kenyan adults with uncomplicated malaria receiving

17. Bergqvist Y, Domez-Nyberg B. Distribution of chloroquine and its metabolite
desethyl-chloroquine in human blood cells and its implication for the quan-
titative determination of these compounds in serum and plasma. J Chromatogr.

18. Ojich AU. Increased accumulation of chloroquine and desethylchloroquine in ho-

19. Adjei GO, Goka BQ, Enweronu-Laryea CC, Rodrigues OP, Reiner L, Sulley AM,
Alifrangis M, Khiali I, Kurtzhals JA. A randomized trial of artesunate-amodi-
quiene versus artemether-lumefantrine in Ghanaian paediatric sickle cell and
non-sickle cell disease patients with acute uncomplicated malaria. Malar J.


Bunch C, Warrell DA. Pharmacokinetics of intravenous amodiaquine. Br J Clin

22. Scarsi KK, Fehlintola FA, Ma Q, Aweke FT, Darin KM, Morse GD, Akinlola IT,
Adedeji WA, Lindegard N, Tarning J, Ongenbude O, Adewole IF, Taiwo B, Mur-
phy RL, Akinyinka OO, Parikh S. Disposition of amodiaquine and desethylamodi-
quiene in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral

23. Hombhanje PW, Hwahwange J, Tsukahara T, Saruwatari J, Nakagawa M, Os-
awa H, Panui MM, Takahashi N, Lum JK, Aumora B, Masta A, Sapuri M,
Kobayakawa T, Kaneko A, Ishizaki T. The disposition of oral amodiaquine in
2005;56(9):298–301.

24. Ware RE, Rees RC, Sarnaik SA, Iyer RV, Alvarez OA, Casella JF, Shulkin BL, Shal-
ably-Rana E, Strife CF, Miller JH, Lane FA, Wang WC, Miller ST. BABY HUG Investi-
gators. Renal function in infants with sickle cell anemia: baseline data from the

25. Audard V, Bartolucci P, Stehle T. Sickle cell disease and albuminuria: re-
cent advances in our understanding of sickle cell nephropathy. Clin Kidney J.

26. Etteldorf JN, Smith JD, Turtle AH, Diggs LW. Renal hemodynamic studies in

27. Gremse DA, Fillingim E, Hoff CJ, Wells DJ, Boerth RC. Hepatic func-
tion as assessed by lidocaine metabolism in sickle cell disease. J Pediatr.

28. NATH KA, Katsic ZS, Gladwin MT. The perfusion paradox and vascular instabil-

29. Darbari DS, Neely M, van den Anker J, Rana S. Increased clearance of

30. Gremse DA, Fillingim E, Hoff CJ, Wells DJ, Boerth RC. Hepatic func-
tion as assessed by lidocaine metabolism in sickle cell disease. J Pediatr.

31. Facchin A, Bui S, Leroux S, Nacks F, Koehl B, Maksud E, Fayon M, Jacq-
Aigrain E, with the assistance of the Paediatric Clinical Investigation Cen-
tres Pharmacology Group. Variability of ciprofloxacin pharmacokinetics in chil-
2018;73(12):3423–3429.

32. Maksud E, Koehl B, Facchin A, Ha P, Zhao W, Kaguelidou F, Benkerrou M,
Mariani P, Faye A, Lorrot M, Jacq-Aigrain E. Population Pharmacokinetics of Ce-
ofotaxime and Dosage Recommendations in Children with Sickle Cell Disease.

position in sickle cell patients compared with healthy volunteers. J Clin Phar-

34. Zemel BS, Kowchak DA, Ohene-Frempong K, Schall JL, Stallings VA. Effects of
delayed pubertal development, nutritional status, and disease severity on lon-
gitudinal patterns of growth failure in children with sickle cell disease. Pediatr

35. Cox SE, Makani J, Fulford AJ, Komba AN, Soka D, Williams TN, New-
ton CR, Marsh K, Prestige AM. Nutritional status, hospitalization and mor-
tality among patients with sickle cell anemia in Tanzania. Haematologica.
2011;96(7):948–953.

with sickle cell disease at Korle Bu Teaching Hospital, Accra, Ghana. West Afr J